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Key Points
• Skeletal muscle myosin promotes thrombus formation and enhances prothrombin activation by binding factors Xa and Va.
• The procoagulant activity of skeletal muscle myosin might contribute to the hypercoagulability in plasmas of acute trauma patients.
D e g u c h i e t a l .
Abstract
To test the hypothesis that skeletal muscle myosins can directly influence blood coagulation and thrombosis, ex vivo studies of the effects of myosin on thrombogenesis in fresh human blood were conducted. Addition of myosin to blood augmented the thrombotic responses of human blood flowing over collagen-coated surfaces (300 s -1 shear rate). Perfusion of human blood over myosin-coated surfaces also caused fibrin and platelet deposition, evidencing myosin's thrombogenicity. Myosin markedly enhanced thrombin generation in both platelet rich plasma and platelet poor plasma, indicating that myosin promoted thrombin generation in plasma primarily independent of platelets. In purified reaction mixtures composed only of factor Xa, factor Va, prothrombin and calcium ions, myosin greatly enhanced prothrombinase activity. The
Gla domain of factor Xa was not required for myosin's prothrombinase enhancement. When binding of purified clotting factors to immobilized-myosin was monitored using Bio-Layer
Interferometry, factors Xa and Va each showed favorable binding interactions. Factor Va reduced by 100-fold the apparent Kd of myosin for factor Xa (Kd ~ 0.48 nM), primarily by reducing k off , indicating formation of a stable ternary complex of myosin:Xa:Va. In studies to assess possible clinical relevance for this discovery, we found that anti-myosin antibodies inhibited thrombin generation in acute trauma patient plasmas more than in control plasmas (p=0.0004), implying myosin might contribute to acute trauma coagulopathy. We posit that myosin enhancement of thrombin generation could contribute either to promote hemostasis or to augment thrombosis risk with consequent implications for myosin's possible contributions to pathophysiology in the setting of acute injuries.
Introduction
Thrombin is generated in blood by proteolytic activation of prothrombin by factor Xa, factor Va, and Ca ++ assembled on a suitable surface. 1, 2 Insufficient or excessive thrombin generation is associated with bleeding or thrombosis, respectively. Knowledge of the molecular surfaces that regulate thrombin generation is essential. Recent studies emphasize that thrombin generation primarily occurs at the site of damaged endothelium and exposed subendothelium, not primarily on the membranes of activated platelets. 3, 4 Thus, damaged cells, subendothelial basement membranes, and damaged tissues may provide procoagulant surfaces that contribute to thrombin generation. A variety of molecular and structural elements distinct from phosphatidylserine or phospholipid membranes are procoagulant, including collagens that are prothrombotic via both platelet activation [5] [6] [7] and contact activation mechanisms. 8, 9 Murine and primate in vivo thrombosis model studies 10,11 are consistent with prothrombotic mechanism for collagens. Collagens bind factor IX 12 and a mouse model with a variant of factor IX defective in collagen binding manifests impaired hemostasis. 3 Laminins are procoagulant via both platelet activation and contact activation. 5, [7] [8] [9] [10] [11] [12] [13] [14] Polyphosphates and polynucleotides support contact activation and other procoagulant reactions, 2, 15 but none of these enhances prothrombinase activity.
In a pilot exomics rare variant genotyping study targeting low frequency exomic variants for their potential association with venous thrombosis. 16 we linked a cluster of skeletal muscle myosin heavy chain gene rare missense variants to venous thrombosis. But myosin is not a member of any conventional pathway affecting thrombosis or hemostasis. Thus, here we report our testing of the hypothesis that myosin can directly influence blood coagulation and thrombosis. We report the remarkable direct effects of skeletal muscle myosin on thrombin generation and fibrin formation in ex vivo studies of flowing human blood and in vitro in thrombin
generation assays using both plasma assays and purified prothrombinase assays due to myosin's ability to bind factors Xa and Va. Moreover, myosin is here implicated as potentially contributing to the thrombin generation potential in plasma from severely injured patients presenting with acute traumatic coagulopathy.
Materials and Methods
Additional information for some Methods is provided in Supplemental Materials and Methods.
Materials
See Supplemental Materials.
Acute Trauma Plasmas
Citrated plasma from acute trauma patients (N=26) and healthy control (N=10) were obtained from a single Level 1 Trauma Center. 17 Blood samples were collected from severely injured acute trauma patients immediately upon arrival at a level 1 trauma center at the emergency department (San Francisco General Hospital). After a waiver of consent was applied for initial blood draws, informed consent was obtained from all patients, as approved by the University of California Committee on Human Research. Healthy control citrated control plasmas came from 20 healthy consenting adults (10 male, 10 female). 10 controls were recruited through the Scripps blood donation program and 10 controls through the UCSF Level 1 trauma center.
Blood plasmas were stored at -70ºC. All study subjects provided informed consent according to each institution's approved protocols.
Ex vivo whole blood perfusion experiments
The prothrombotic effects of myosin using fresh recalcified whole human blood under flow conditions was tested as described previously for studies presented in Figure 1 18 and in Figure   S1 . 19 The ex vivo whole blood perfusion studies used in Figure 1 followed procedures as described. 18 For collagen-coated surfaces, 1.0 mg/ml of acid insoluble collagen type I was coated on glass slides for 1 hr, washed with HBS and incubated 1 hr with 1 mg/ml BSA/HBS. 
Thrombin generation assays using freshly prepared PRP were performed as described 20 with some minor modifications. Platelet poor plasma (PPP) from the same individual donor who provided PRP or pooled normal human PPP were also tested for the plasma thrombin generation assay in the presence or absence of 4 µM PC/PS (80 %:20 %) vesicles. Plasmas from acute trauma patients and controls were assayed using tissue factor induced-thrombin generation assays, as described above, in the presence of either polyclonal antiserum against myosin heavy and light chains or nonimmune control antiserum.
Activation of prothrombin by prothrombinase complex
Myosin or PCPS vesicles were incubated with factor Va (5 nM, final) and factor Xa (0. 
Statistical analysis
Mann Whitney t-test and Km calculations were performed using Prism™ 4.03 software (Graph Pad Software Inc., San Diego, CA).
Results

Skeletal muscle myosin promotes thrombus formation in flowing blood
To assay the prothrombotic effects of myosin, recalcified fresh whole human blood was perfused over either collagen-coated, BSA-coated or myosin-coated chambers at the initial wall shear rate of 300 s -1 . 18 Typical patterns of platelet deposition and fibrin deposition on the collagen-coated surface were seen in the absence of added myosin after 4 min perfusion as shown by images and by quantification ( Figure 1A) . The prothrombotic activity of myosin was assessed by adding it to blood before perfusion over a collagen-coated surface; remarkably, addition of myosin to blood resulted in more extensive fibrin strand formation on the collagen surface but not greater platelet deposition ( Figure 1A ), indicating myosin under these conditions was procoagulant. To assess if myosin can support platelet deposition and fibrin formation directly, recalcified fresh whole human blood was perfused over a myosin-coated surface. The
results show that immobilized myosin supported platelet deposition on which fibrin deposition was enriched in flow-oriented strands ( Figure 1B) . In controls, recalcified flowing fresh human blood failed to form fibrin strands or to deposit platelets on BSA-coated surfaces (data not shown).
A different experimental design that employed recalcified whole human blood flowing through myosin-coated capillaries and that analyzed thrombus formation after fixation 19 was also employed to evaluate the myosin's prothrombotic effects. Recalcified fresh human blood was perfused over the myosin-coated surface under shear at 300 s -1 for 10, 20 and 30 min.
When thrombus formation was subsequently visually recorded using differential interference contrast (DIC) microscopy, myosin supported time-dependent increases in platelet adhesion and aggregation and fibrin formation over 10 to 30 min ( Figure S1 , upper panels). Fibrin strands were visible throughout the myosin-coated capillary at 20 to 30 min ( Figure S1 ).
Similarly, fluorescent light microscopy detected fibrin deposition (see blue stain in Figure S1 , bottom panels) and platelet aggregation (see green for P-selectin deposition and red for integrin α IIb deposition in Figure S1 , bottom panels) following the perfusion of whole blood over a myosin-coated surface, agreeing with the observed platelet and fibrin deposition detected by DIC microscopy. In controls, fibrin deposition and platelet aggregation were not visibly detected on BSA-coated surfaces ( Figure S1 ). Thus, skeletal muscle myosin's prothrombotic properties were shown using two different methods for visualization of thrombi in two independent ex vivo studies using fresh human blood (Figures 1 and S1 ).
Effect of rabbit skeletal muscle myosin on thrombin generation in plasma
Because there were no previous reports linking myosin to clotting reactions, we studied the effects of skeletal muscle myosin on thrombin generation in plasma. In a concentrationdependent manner, purified rabbit myosin enhanced thrombin generation in platelet rich plasma
(PRP) when either 0.5 pM tissue factor (TF)/Ca ++ ions (Figure 2A ) or simple recalcification was used to induce thrombin generation ( Figure 2B) . Similarly, thrombin generation in platelet poor plasma (PPP) was stimulated by myosin when the plasma was freshly prepared from the same source blood used for making PRP and subjected to TF/Ca ++ or Ca ++ alone ( Figure 2C, 2D) .
Thus, the ability of myosin to enhance thrombin generation in plasma was primarily independent of platelets. Furthermore, when 0.1 pM or 0. 
Skeletal muscle myosin effects on purified prothrombin activation by purified factors Xa and Va
The final common and most critical step for the extrinsic and intrinsic coagulation pathways involves prothrombin activation to generate thrombin. The potential for myosin to enhance activation of purified prothrombin by purified factor Xa, factor Va, and Ca ++ ions (termed the prothrombinase complex) was discovered to be highly noteworthy and led us to perform detailed kinetic studies of prothrombin activation at varying concentrations of myosin and of prothrombin ( Figure 4A, 4B) . Similar kinetic studies were performed in parallel on the ability of PCPS phospholipid vesicles containing 20% phosphatidylserine to enhance prothrombinase activity (Figure 4 B) . Myosin variation, like phospholipid variation, enabled good fits for kinetic parameters for prothrombin activation by the enzymatic complex comprising factors Xa:Va:Ca ++ .
Analysis of the kinetic data yielded the Km of 0.5 μ M prothrombin for myosin-enhanced prothrombin activation (Table S1 ). Based on curve fitting of data in Figure 4B , for myosinenhanced prothrombinase, Vmax was 836 ± 71 /min moles of thrombin per mole of factor Xa.
For PCPS-enhanced prothrombinase ( Figure 4B ), Vmax was 429 ± 11 /min moles of thrombin per mole of factor Xa.
When Gla domainless (DG)-factor Xa was assayed, myosin retained > 30 % prothrombinase activity ( Figure 4D ) whereas, as expected, [21] [22] [23] DG-factor Xa lost > 98 % activity in assays using procoagulant phospholipids ( Figure S2) . Thus, the Gla domain which is absolutely essential for phospholipid-enhanced procoagulant activity was not required for myosin's enhancement of prothrombinase activity. When prothrombinase assays were done with factor Xa, prothrombin, Ca ++ ions and myosin (2 -40 nM), but without addition of factor Va, no significant activation of prothrombin was observed (± 15%) (data not shown). Thus, factor
Va was required for myosin's potent enhancement of prothrombinase activity.
To prove that the myosin molecule itself in the skeletal muscle myosin preparation is procoagulant, different myosin-targeting reagents were employed. We used two allosteric inhibitors of myosin, MyoVin-1 and trifluoperazine (TFP) 24 which alter myosin's conformation and functional activity, and also anti-myosin polyclonal antibodies to study their ability to inhibit myosin's enhancement of prothrombinase activity. Indeed, each one of the myosin allosteric inhibitors and the anti-myosin antibodies blocked by > 80 % myosin's prothrombinaseenhancing action ( Figure 4C ). In controls, these anti-myosin antibodies did not inhibit prothrombin activation by factor Xa/factor Va in the absence of myosin nor did they inhibit factor X activation by tissue factor/factor Vlla ( Figure S3) . In other studies, pulldown of myosin from myosin solutions using monoclonal anti-myosin heavy chain antibody-beads but not control nonimmune-monoclonal antibody-beads removed > 85 % of myosin's procoagulant activity ( Figure 4C ). These combined data indicate that the myosin molecule itself in the myosin preparations is required for the observed enhancement of prothrombin activation by factors Xa and Va in the purified prothrombinase assay mixtures, leading to the hypothesis that myosin binds factors Xa and Va.
Bio-Layer Interferometry binding studies
To define direct interactions between myosin and factor Xa or factor Va, we used Bio-Layer
Interferometry (BLI) with the Octet Red system to record the kinetics for binding of inhibited (i) factor Xai and of factor Va to myosin that was immobilized on the Octet Red probe which carried a monoclonal anti-myosin antibody. Factor Xa was irreversibly inhibited by DEGR-chloromethyl ketone to prevent proteolysis during the study. Factor Xai bound to myosin with a Kd of 51 nM 
Myosin-dependent contributions to thrombin generation in acute trauma and normal plasmas When added to plasma before initiating tissue factor-induced thrombin generation, polyclonal anti-myosin antibodies modestly but significantly reduced thrombin generation in plasma whereas control polyclonal antibodies did not ( Figure S3) . When the effects of anti-myosin antibodies on thrombin generation in plasmas from acute trauma subjects 17 were compared to results for healthy control subjects, the reduction of thrombin peak median value by anti-myosin antibodies was 28% for acute traumatic coagulopathy patients which was significantly greater than the 17% value for healthy control subjects (p=0.0004, Mann Whitney test) ( Figure 6A ).
When the thrombin generation data of this study were quantified in terms of absolute molar amounts of thrombin generation, the reduction of thrombin peak concentration by anti-myosin antibodies was 22 nM which was almost two-fold greater than that for control plasmas (13 nM) (p=0.0026, Mann Whitney test) (Figure 6B ), implying that myosin-related thrombin generation potential was almost twice as much in acute trauma plasmas than in healthy subjects' plasmas.
Discussion
Studies that were conducted to test the hypothesis that muscle myosin can contribute functional activity to prothrombotic mechanisms 16 established the remarkable prothrombotic activities of myosin. Ex vivo experiments using flowing fresh human blood showed that surfaces coated with rabbit skeletal muscle myosin, which is ~95% homologous to human skeletal muscle myosin, substantially promotes both fibrin deposition and platelet deposition. When myosin is added to flowing blood that is exposed to collagen-coated surfaces, fibrin deposition was greatly increased over that seen in controls, indicating that myosin particularly promotes fibrin strand formation in flowing blood. The impression that myosin particularly promotes fibrin formation
was strengthened by results from in vitro studies which showed that in either platelet rich plasma or platelet poor plasma, skeletal myosin enhances thrombin generation. This finding showed that myosin strongly exerts procoagulant activity even in plasma without platelets.
To identify potential mechanisms for myosin's enhancement of thrombin generation, we focused on the most critical step which is common to the extrinsic and intrinsic coagulation pathways, namely prothrombin activation. In prothrombinase assays comprising only myosin and clotting factors, myosin strongly enhances prothrombin activation. This was true whether or not substantial levels of procoagulant phospholipid vesicles, e.g., 4 µM PCPS, were added to the reaction mixtures. Moreover, myosin supports the activation of prothrombin by Gladomainless-factor Xa and factor Va whereas phospholipid vesicles fail to do so, thereby defining a unique attribute of myosin's ability to promote thrombin generation.
Consistent with the hypothesis that myosin assembles the prothrombinase factor
Xa:factor Va complex on its surface, myosin is capable of binding both factor Xa and factor Va individually, and the latter factor greatly enhances the binding of the former factor such that the dissociation constant of factor Xa for myosin is below 1 nM in the presence of factor Va. Thus, the functional assays and biophysical binding studies provide a clear mechanism for the ability of myosin to enhance thrombin generation, namely that myosin assembles a stable prothrombinase complex.
Another remarkable finding in this report is the fact that analysis of the enzyme kinetics for myosin's enhancement of prothrombinase activity (Fig. 4B) 
phospholipid enhancement of prothrombinase 24-27 (see Table S2 ) indicates that myosin exerts a procoagulant potency within the generally reported range for PCPS vesicles.
Our findings provoke a potential paradigm shift for how surface-bound prothrombinase activities might contribute to hemostasis or thrombosis when blood encounters damaged tissues that expose procoagulant myosins. Tissue damage exposes cytoskeletal and extracellular matrix structural proteins and intracellular proteins, including laminins, collagens, tissue factor and polyphosphates that trigger platelet activation and/or that can stimulate activation of intrinsic pathway and extrinsic pathway. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] These reactions that are promoted by exposed structural proteins initiate activation of the intrinsic pathway and the extrinsic pathway to generate factor Xa. In turn, the structural protein, myosin, can bind factor Xa with factor Va to form a stable, potent prothrombinase complex (see Figure 7) . This new scheme for a novel prothrombinase complex and thrombin generation must be integrated with currently appreciated clotting Plasma myosin heavy or light chain levels were reported to be relatively elevated by seven-fold
to ten-fold above baseline in patients with muscle damage (i. One implication of the hypothesis that myosin is procoagulant (Figure 7) is that acute trauma with extensive tissue damage might lead to myosin-induced thrombin generation where factor Xa is generated, potentially with either beneficial or pathologic consequences. Studies of TF-induced thrombin generation in plasma showed that anti-myosin antibodies reduce thrombin generation significantly more in plasmas from patients with acute traumatic coagulopathy than in controls' plasmas, i.e., by 28 % vs. 17% (p< 0.0004). This indicates that myosin, which circulates in human plasma, may contribute significantly more to the procoagulant potential of acute trauma patient plasmas than to that of healthy controls' plasmas. Further detailed studies of the potential contributions of myosins to post-injury dyshomeostasis as a result of massive tissue injuries are warranted.
In summary, we discovered that skeletal muscle myosins exert prothrombotic activity in flowing whole blood and procoagulant activity in plasma. Studies using purified clotting factors
show that myosin enhances thrombin generation due to binding of factors Xa and Va. Myosin in acute trauma patients' plasmas significantly increases the potential for thrombin generation compared to controls. These findings define a mechanism for myosin's procoagulant activity
and imply that myosin might significantly and physiologically contribute to achieve hemostasis and/or to promote thrombosis. 
Binding studies using BLI were conducted with factor Xai, DG-factor Xai, factor Va, factor Xai in the presence of factor Va, and factor IXai. Proteins were in buffer containing 50 mM Tris, pH The intrinsic and extrinsic coagulation pathways converge at the generation of factor Xa which is the key enzyme that activates prothrombin. As depicted here, both factor Xa and its cofactor, factor Va, bind to myosin which potently promotes prothrombin activation to generate thrombin.
Extensive data in this report lead to this novel scheme for prothrombin activation which may occur on the surface of myosin independent of any particular cell surface. 
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